Newsroom

Sorted by: Latest

-

BGC Group Updates its Outlook for the Fourth Quarter of 2025

NEW YORK--(BUSINESS WIRE)--BGC Group, Inc. (Nasdaq: BGC), today announced that it has updated its outlook for the quarter ending December 31, 2025. Updated Outlook BGC reaffirmed its previously stated outlook ranges for revenue and pre-tax Adjusted Earnings for the fourth quarter of 2025. The Company’s outlook was contained in BGC’s financial results press release issued on November 6, 2025, which can be found at http://ir.bgcg.com. Non-GAAP Financial Measures The non-GAAP definitions below inc...
-

Nicokick and Northerner Close Out 2025 with Unwavering Commitment to Responsible Online Retailing

WASHINGTON--(BUSINESS WIRE)--Nicokick and Northerner, leading online retailers for nicotine pouches and modern oral products in the United States, reaffirmed their commitment to setting and maintaining the highest standard for responsible, compliant, and transparent online retailing of nicotine pouches for adults aged 21 and over. This announcement comes in light of the U.S. Food and Drug Administration’s recent announcements that outline a clearer path for regulation and category standards. Th...
-

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted Motiva® implants for approval in primary and revision breast reconstruction to the U.S. Food and Drug Administration (FDA). The products were previously approved by the FDA for use in breast augmentation on September 27, 2024. “Expanding our FD...
-

Enveric Biosciences Announces Patent Issuance

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of U.S. Patent No. 12,492,179 entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives” (the “‘179 patent”), with claims to compositions and methods of treatment for novel molecules with the potential to be developed...
-

Robbins Geller Rudman & Dowd LLP Announces Pending Class Action Lawsuit in the ExxonMobil Securities Litigation

SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the ExxonMobil Securities Litigation: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF TEXAS DALLAS DIVISION PEDRO RAMIREZ, JR., Individually and on Behalf of All Others Similarly Situated,   Civil Action No. 3:16-cv-03111-K         CLASS ACTION     Plaintiff, vs.         EXXON MOBIL CORPORATION, et al.,         Defendants. SUMMARY NOTICE OF PENDENCY OF CLASS ACTION TO: ALL PER...
-

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. (“Halda”), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. “This strategic milestone underscores our commitment to r...
-

GE HealthCare management to present at upcoming investor conference

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the JP Morgan 44th Annual Healthcare Conference in San Francisco, CA on January 13, 2026, at 10:30 a.m. PT/1:30 p.m. ET/12:30 p.m. CT. A webcast of this event can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the date and time listed above. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading...
-

Eagle Point Credit Company Inc. Announces Full Redemption of the 8.00% Series F Term Preferred Stock Due 2029

GREENWICH, Conn.--(BUSINESS WIRE)--Eagle Point Credit Company Inc. (the “Company”) (NYSE: ECC, ECCC, ECC PRD, ECCF, ECCU, ECCV, ECCW, ECCX) today announced the full redemption of the Company’s 8.00% Series F Term Preferred Stock due 2029 (NYSE: ECCF) (“Series F Term Preferred Stock”) on January 30, 2026 (the “Redemption Date”). The redemption price of the Series F Term Preferred Stock will be $25 per share. This redemption reflects the Company’s ongoing efforts to optimize its capital structure...
-

SkyMirr to Showcase Breakthrough Wireless Technologies at CES 2026

MELBOURNE, Fla.--(BUSINESS WIRE)--SkyMirr announces its CES 2026 showcase, featuring advanced 5G, IoT, and antenna technologies, demos, and a limited-time Sky5G introductory offer...
-

South Africa Plastics and Plastic Products Manufacturing Industry Report 2025, Profiles of Sasol, Safripol, Mpact, Alpla Packaging, Polyoak Packaging, Transpaco, and Apex Cordset - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Manufacture of Plastics and Plastic Products in South Africa 2025" report has been added to ResearchAndMarkets.com's offering. This report on the manufacture of plastics and plastic products provides information on the size and state of the industry, including polymer sales, consumption and demand, capacity utilisation, and recycling. It examines growth trends, inventory destocking, shifts in product mix, feedstock security and import protection, as well as notable...